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Background: Abediterol (LAS100977) is a novel, long-acting b2-agonist, in development for the
once-daily treatment of asthma in combination with mometasone. Here we report the results
of a Phase IIa trial of single doses of abediterol added to ongoing maintenance therapy (inhaled
corticosteroids) in patients with persistent mild-to-moderate asthma.
Methods: This was a randomised, double-blind, placebo- and active-comparator-controlled,
five-way crossover study. Male patients (18e70 years) with a clinical diagnosis of persistent
asthma received abediterol (5, 10 and 25 mg), salmeterol and placebo, on top of ongoing main-
tenance therapy. Lung function was determined using spirometry and whole body plethysmog-
raphy. The primary efficacy endpoint was change from baseline in trough forced expiratory
volume in 1 s (FEV1) after a single dose.
Results: All three abediterol doses induced statistically significant increases in trough FEV1 vs
placebo and salmeterol. Improvements in other lung function parameters were also statisti-
cally significantly greater with all abediterol doses vs both placebo (p < 0.0001) and salmeterol
(p < 0.05) than the first assessment at 5 min post-dose. These improvements were sustained to
36 h post-dose. The profile of treatment-emergent adverse events judged as related to abedi-
terol was consistent with that seen after adrenergic stimulation and occurred exclusively in
patients who received abediterol 10 mg or 25 mg.
Conclusions: This first-in-patient study revealed the potent, rapid and long-acting bronchodi-
latory effect of abediterol in patients with persistent mild-to-moderate asthma together withtory Research, Biebricher Allee 34, 65187 Wiesbaden, Germany. Tel.: þ49 611 9854410; fax: þ49 611
i.de, jutta-beier@gmx.de (J. Beier).
14.08.005
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
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Asthma is a chronic, inflammatory respiratory disorder
characterised by episodes of wheezing, breathlessness,
chest tightness and coughing [1]. Asthma is thought to
affect around 300 million individuals of all ages worldwide
and is associated with a considerable morbidity burden and
an increased risk for death [1].
Asthma management strategies aim to control daily
symptoms and reduce the risk for asthma exacerbations.
Current asthma guidelines recommend the use of long-acting
bronchodilators such as long-acting b2-agonists (LABAs) in
conjunction with inhaled corticosteroids (ICS) for the man-
agement of patients with moderate-to-severe asthma [1,2].
This dual approach addresses both the daily symptomatic
burden of moderate-to-severe asthma and the underlying
inflammatory processes that are thought to increase the risk
for episodic exacerbations. Currently available LABAs
include salmeterol, formoterol, indacaterol (not approved
for the treatment of asthma) and olodaterol. Whilst they are
effective in terms of bronchodilation, there are safety con-
cerns surrounding the use of LABAmonotherapies in asthma,
an approach which is thought to increase the risk for asthma-
related adverse events [3]. Indeed, an FDA black boxwarning
states that salmeterol and formoterol may only be used in
combination with ICS in patients with asthma.
Abediterol (LAS100977) is a novel, potent and selective
LABA, currently in clinical development for the once-daily
treatment of chronic obstructive pulmonary disease (COPD)
and asthma in combination with an ICS. The preclinical eval-
uation of this agent demonstrated a high potency and selec-
tivity at the b2-receptors, with a rapid onset of
bronchodilation and long duration of action [4]. A Phase I,
first-in-human, single-dose clinical trial, showed a potent
bronchodilatory effect of abediterol at doses ranging from
5mg to50mg [5], confirming preclinical dataobtainedwith this
compound. The safety and tolerability profile in healthy
adults was encouraging with no treatment-emergent adverse
events (TEAEs) reported at the lowest dose (5 mg) and a single
case of moderate palpitations in the highest dose group
(50 mg; all other TEAEs were mild in intensity). This paper
reports data from an active comparator (salmeterol) and
placebo-controlled proof-of-concept Phase IIa trial of single
doses of abediterol (5 mg, 10 mg or 25 mg) added to ongoing
maintenance therapy with ICS in a stable dose regimen in
patients with mild-to-moderate persistent asthma.Methods
This was a Phase IIa, randomised, double-blind, double-
dummy,placebo-andactive-comparator-controlled,five-way
crossover study. The studywas carried out in accordancewith
the Declaration of Helsinki (1964 and subsequent amend-
ments) and with Good Clinical Practice and Good Laboratoryline with European directives 2001/20/RC and 2005/29/EC.Study subjects
The study included male patients aged 18e70 years with a
clinical diagnosis of mild-to-moderate persistent asthma for
at least 6 months prior to screening. Female patients did not
take part in the current study as the requisite preclinical
evaluations had not been completed at the time the study
was initiated. Eligiblepatientswere required to havea stable
maintenance therapy of ICS during the 6 weeks prior to the
screening visit, either aloneor in combinationwith a short- or
long-acting b2-agonist. They were also required to have a
forced expiratory volume in 1 s (FEV1) between 60% and 85%
of the predicted normal pre-bronchodilator value at
screening, FEV1 reversibility 12% and an absolute increase
of at least 200 mL over baseline value following inhalation of
400 mg salbutamol. In addition, the pre-dose FEV1 for each
treatment period had to be within 80e120% of the pre-dose
FEV1 at screening. Exclusion criteria included a history of
smokingduring theprevious 12months anda10pack-years,
the presence of clinically significant diseases, other than
asthma, hospitalisation or emergency-room treatment for
acute asthma in the 6 weeks prior to screening.Study drug
After an initial screening and run-in period of up to 14 days,
patients were randomised 1:1:1:1:1 to one of 5 treatment
sequences during which they received once-daily abediterol
(5, 10 and 25 mg), salmeterol 50 mg twice daily or placebo in
addition to ongoing ICS maintenance therapy. Ongoing
asthma medications were withdrawn during the run-in
period, with the exception of ICS and rescue medication.
All study drugs were delivered as dry powder for inhalation.
Abediterol doses were administered in themorning as a single
inhaled dose delivered via the Cyclohaler device. Salme-
terol was administered in twice daily (BID) inhaled doses, one
in the morning and one in the evening, via the Accuhaler
device. A double-dummy approach was taken to maintain
blinding as the study drugs were delivered in different inha-
lation devices and corresponding placebo treatments were
administered using the Cyclohaler and Accuhaler devices.
Each treatment period lasted 36 h, with a minimum 7-day
washout period between consecutive treatments. Patients
were properly washed out between each study period and
asthma stability was re-checked. Patients were allowed to
use their pre-existing long-acting bronchodilators during the
washout periods, but these were withdrawn 72 h prior to the
next treatment period. During treatment periods, only ICS
and asthma rescue medication (100 mg/puff of salbutamol
pressurised metered dose inhaler) were permitted; rescue
medication was not permitted within 6 h prior to a study visit.
Table 1 Baseline characteristics of the study population
(safety population).
Characteristic N Z 25
Age, mean (SD) years 44.2 (10.3)
BMI, mean (SD) kg/m2 27.1 (2.5)
Smoking history, n (%)
Non-smokers 20 (80)
Ex-smokers
(8e20 cigarettes/day)
5 (20)
Duration of asthma (years) 21.7 (11.8)
Asthma category, n (%)
60% to <80% predicted FEV1 17 (70)
80% predicted FEV1 8 (30)
FEV1, mean (SD)
Pre-salbutamol (L) 2.90 (0.45)
Pre-salbutamol % of
predicted value
73.89 (6.75)
Change from
pre-salbutamol (L)a
0.71 (0.31)
Percent of change
from pre-salbutamola
24.68 (10.85)
BMI, body mass index; FEV1, forced expiratory volume in 1 s; SD,
standard deviation.
a Reversibility defined as 12% increase in pre-salbutamol
FEV1 and a minimum absolute increase of 200 mL.
Figure 1 Change (SE) from baseline in trough FEV1 after one
day of treatment (PP population).
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Spirometry was performed before study drug administration
(baseline) and at 5, 15 and 30 min, and at 1, 2, 3, 4, 6, 8,
12, 14, 23, 24 and 36 h post-dose. For spirometry, FEV1,
forced vital capacity (FVC), peak expiratory flow (PEF), and
forced mid-expiratory flow (FEF25e75) were determined.
Body plethysmography was performed at baseline and at 1,
2, 4, 6, 12, 24 and 36 h post-dose to determine airway
resistance (Raw) and specific airway conductance (sGaw).
The primary efficacy endpoint was change from baseline
in trough FEV1 after one day of treatment, expressed as the
mean of the 23- and 24-h post-administration values. Sec-
ondary endpoints included the change from baseline in
FEV1, FVC, PEF, and FEF25e75, Raw and sGaw.
Safety and tolerability assessments included reporting of
adverse events, 12-lead electrocardiogram (ECG), physical
examination, laboratory tests relating to safety evaluation,
and recording of vital signs (pulse rate and blood pressure).
Pharmacodynamic laboratory evaluations were conducted
for serum potassium and glucose levels.
Statistical analyses
The analysis of the efficacy variables was performed on the
per protocol (PP) population (those patients satisfying the
main inclusion/exclusion criteria liable to affect the effi-
cacy assessments, completed all treatment periods and did
not present serious violations of the protocol) using a
descriptive approach. The primary efficacy variable
(change from baseline in trough FEV1) and secondary effi-
cacy variables were also analysed using Analysis of Covari-
ance (ANCOVA) models for crossover designs. Missing data
were not imputed and an observed cases (OC) approach was
used. Safety and tolerability assessments, number of
withdrawals and concomitant medication use were ana-
lysed descriptively for the safety population (all patients
who received at least one dose of study drug).
Data were analysed using the SAS software (version 8.2).
Results
Patients
A total of 25 male patients with mild-to-moderate persistent
asthma were enrolled and randomised to one of the 5
treatment sequences in this first-in-patient study. Table 1
provides a summary of the baseline characteristics of the
study population. One patient was not included in the PP
population due to the inhalation of rescuemedication during
treatment period 1 (considered a major protocol violation).
Efficacy
Primary endpoint
Single inhaled doses of abediterol (5 mg, 10 mg and 25 mg)
induced statistically significant increases in trough FEV1
compared with placebo and salmeterol (50 mg BID) (Fig. 1).
At the first post-dose measurement (5 min post-dose) all
abediterol doses (5 mg, 10 mg and 25 mg) statisticallysignificantly improved lung function compared with placebo
(p < 0.0001) and salmeterol (p < 0.05), and showed in-
creases versus their respective baseline values that indi-
cated a rapid onset of action (Fig. 2). At all doses tested,
abediterol provided sustained bronchodilation for the
entire 36-h duration of the study period. Increases in FEV1
were observed at all timepoints and were statistically
significantly greater than placebo (p < 0.0001) and salme-
terol 50 mg BID (p < 0.05) (Fig. 3).
Secondary endpoints
The secondary lung function endpoints, change from
baseline in FVC, PEF, and FEF25e75, were also statistically
significantly improved with all abediterol doses compared
with placebo and salmeterol. All abediterol doses
Figure 2 Change from baseline in FEV1 0e60 min post-dose
(PP population).
A
B
Figure 4 Change from baseline in Raw (Panel A) and sGaw
(Panel B) over 36 h post-dose (PP population).
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first post-dose measurement (1 h post-dose) and at all
remaining timepoints post-dose to 36 h (Fig. 4(A)).
Compared with baseline, mean sGaw values increased with
all abediterol doses starting at the first post-dose mea-
surement (1 h post-dose) and at all remaining timepoints
post-dose to 36 h (Fig. 4(B)). There were no doseeresponse
relationships for abediterol from 5 mg to 25 mg on spirom-
etry or body plethysmography parameters.
Safety and tolerability
Overall, 21 (84%) of the 25 patients who participated in the
study reported 66 TEAEs. Of these, 8 were reported in the
abediterol 5 mg group (20% of patients), 12 in the 10 mg
group (36% of patients), 40 in the 25 mg group (68% of pa-
tients), 2 in the salmeterol group (8% of patients), and 4 in
the placebo group (16% of patients). The most frequently
reported drug-related TEAEs were tremor (17 episodes in 10
patients), restlessness (8 episodes in 6 patients) and
nervousness (4 episodes in 4 patients), which were exclu-
sively reported at the two highest doses of abediterol (10 mg
and 25 mg) (Table 2). Only one drug-related TEAEFigure 3 Change from baseline in FEV1 over 36 h post-dose
(PP population).(headache) was reported in the abediterol 5 mg group:
single cases of headache were also reported in the 10 mg
and 25 mg groups. All TEAEs were resolved by the end of the
study.
Most TEAEs were mild or moderate in intensity. Four
severe TEAEs were reported (one case each of vomiting,
nausea, spinal osteoarthritis and headache); all of which
were resolved by the end of the trial. The case of severe
spinal osteoarthritis was classed as a serious TEAE and
occurred in a patient receiving abediterol 10 mg; this event
was not considered by the investigator to be related to
study treatment. A dose-dependent increase in the occur-
rence of TEAEs was observed within the abediterol groups.
No patients were withdrawn from the study due to TEAEs,
and no deaths occurred.
Abediterol had no clinically relevant effects (as judged
by the investigators) on physical examination, laboratory
data, vital signs, or ECG outcomes. A non-clinically relevant
increase in pulse and heart rate was observed at the two
higher doses (10 mg and 25 mg). At 24 h post-dose the heart
rate had returned to that observed at baseline for the 10 mg
dose and remained elevated by around 7 beats per minute
for the 25 mg dose. No clinically relevant increases in QTc
Fridericia were determined for any abediterol dose. A slight
prolongation for QTc Bazett was noted for the 10 mg and
25 mg doses. After the inhalation of all abediterol doses a
Table 2 TEAEs occurring in 1 patient in any treatment group considered to be related to study treatment (safety
population).
Number (%) of patients reporting treatment-related TEAEs
Placebo
(N Z 25)
Salmeterol
50 mg BID
(N Z 25)
Abediterol
5 mg
(N Z 25)
10 mg
(N Z 25)
25 mg
(N Z 25)
Any treatment-related
TEAE
0 (0) 0 (0) 1 (4) 6 (24) 13 (52)
Tremor 0 (0) 0 (0) 0 (0) 2 (8) 10 (40)
Restlessness 0 (0) 0 (0) 0 (0) 1 (4) 6 (24)
Nervousness 0 (0) 0 (0) 0 (0) 2 (8) 2 (8)
Nausea 0 (0) 0 (0) 0 (0) 0 (0) 2 (8)
Tachycardia 0 (0) 0 (0) 0 (0) 1 (4) 1 (4)
Fatigue 0 (0) 0 (0) 0 (0) 0 (0) 1 (4)
Muscular weakness 0 (0) 0 (0) 0 (0) 0 (0) 1 (4)
Dizziness 0 (0) 0 (0) 0 (0) 0 (0) 1 (4)
Headache 0 (0) 0 (0) 1 (4) 1 (4) 1 (4)
Agitation 0 (0) 0 (0) 0 (0) 0 (0) 1 (4)
BID, twice daily; TEAE, treatment-emergent adverse event.
1428 J. Beier et al.trend towards a slight decrease versus baseline was recor-
ded for serum potassium and a slight increase compared
with baseline for serum blood glucose was observed. The
effect on serum potassium was still present at the 36-h
timepoint with the change from baseline ranging from
0.16 mmol/L for the 10 mg dose to 0.24 mmol/L for the
25 mg dose. The effect on glucose was not observed at
either 24 or 36 h post-dose. The change from baseline at
12 h post-dose ranged from 10.8 mg/dL for the 10 mg dose
to 15.1 mg/dL for the 25 mg dose. A slight decrease in serum
potassium and a slight increase in serum glucose were also
noted for salmeterol.Discussion
The results reported here show that single inhaled doses of
abediterol (5 mg, 10 mg and 25 mg) induce a marked bron-
chodilatory effect (lung function tests and body plethys-
mography) that is sustained over the complete observation
period of 36 h post-dose. Abediterol demonstrated a rapid
onset of action with all doses, exhibiting a statistically
significantly greater improvement in lung function begin-
ning at the first measurement timepoint (5 min post-dose)
compared with both placebo and salmeterol for all abedi-
terol doses. These latter results are consistent with pre-
clinical results reported by Aparici and coworkers (2012) [4]
that indicated a rapid and potent bronchodilatory effect for
this agent in isolated human bronchi and a long duration of
action. Taken together, the long duration of bronchodila-
tory action observed in preclinical evaluations [4] and in
the clinical studies, either in this Phase II trial or in the
Phase I study in healthy adults [5] support a once-daily
dosing strategy for abediterol.
In this study, no doseeresponse relationship was iden-
tified in terms of lung function across the three doses of
abediterol evaluated, suggesting that maximal efficacy had
been achieved already with the lowest dose of 5 mg. The
safety and tolerability profile of abediterol in the currentstudy showed a doseeresponse relationship, was consistent
with that expected after adrenergic stimulation and was
observed at the two highest doses tested (10 mg and 25 mg);
the profile for the abediterol 5 mg dose was favourable with
a single case of a TEAE considered to be related to study
drug (headache).
This was a first-in-patient study and at the time of the
design of the trial the likely therapeutic dose range had not
been confirmed, therefore a wide effective dose range was
tested. Subsequent studies have shown that the optimal
dose range to achieve effective bronchodilation with a good
safety and tolerability profile is at the lower end of that
evaluated in the current study [6]. In the Phase II study
reported by Singh and coworkers (2013) [6], 62 male and
female patients with persistent asthma received single
doses of abediterol (0.313 mg, 0.625 mg, 1.25 mg and 2.5 mg),
salbutamol or placebo in a 6-way cross-over trial. Consis-
tent with the results reported here, patients who received
abediterol experienced rapid, marked and sustained bron-
chodilation, with statistically significant benefits compared
with placebo [6]; the safety and tolerability profile of
abediterol in this Phase II study was favourable, with most
TEAEs reported as mild to moderate in intensity, the most
frequent being headache and nasopharyngitis. Together,
these data support the favourable safety and tolerability of
abediterol over a wide dose range from 0.313 mg to 25 mg.
In conclusion, abediterol showed a potent, rapid and
long-acting bronchodilatory effect at all doses tested in
patients with persistent mild-to-moderate asthma, as well
as a good safety and tolerability profile. The promising re-
sults of this proof-of-concept evaluation have prompted
further evaluations of abediterol for the treatment of
asthma and COPD, both alone and in combination with ICS.Acknowledgement
This study was sponsored by Almirall S.A., Barcelona, Spain.
Medical writing support was provided by Tracey Lonergan
Abediterol in patients with persistent asthma 1429on behalf of Complete Medical Communications, and was
funded by Almirall S.A.
References
[1] Global initiative for asthma. 2012. Available from: www.
ginasthma.org [accessed 17.10.12].
[2] British Thoracic Society, Scottish Intercollegiate Guidelines
Network. British guideline on the management of asthma: a
national clinical guideline. 2012. Available from: http://www.
brit-thoracic.org.uk/guidelines/asthma-guidelines.aspx
[accessed 09.13].
[3] Rodrigo GJ, Castro-Rodriguez JA. Safety of long-acting beta
agonists for the treatment of asthma: clearing the air. Thorax
2012;67:342e9.[4] Aparici M, Go´mez-Angelats M, Vilella D, Otal R, Carcasona C,
Vin˜als M, et al. Pharmacological characterization of abedi-
terol, a novel inhaled b(2)-adrenoceptor agonist with long
duration of action and a favorable safety profile in preclinical
models. J Pharmacol Exp Ther 2012;342:497e509.
[5] Timmer W, Massana E, Jime´nez E, Seoane B, de Miquel G,
Ruiz S. Single doses of LAS100977, a novel long acting b2-
agonist, show high activity and long duration in healthy sub-
jects. Am J Respir Crit Care Med 2010;181:A5663 [abs. Pre-
sented at the American Thoracic Society International
Conference, New Orleans, Louisiana, U.S.A. Abstract 4978].
[6] Singh D, Pujol H, Ribera A, Seoane B, Massana E, Astbury C,
et al. Efficacy and safety of abediterol (LAS100977) in stable
asthma: phase II, randomized, crossover study. In: Poster
presented at the European Respiratory Society Annual
Congress, Barcelona, Spain, September 7e11 2013; 2013.
